FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083001514> ?p ?o ?g. }

• W2083001514 endingPage "117" @default.
• W2083001514 startingPage "110" @default.
• W2083001514 abstract "Results of a recent study on human ovarian cancer cell lines indicated that overexpression of dihydrodiol dehydrogenase (DDH) was associated with resistance to cisplatin and disease progression. We examined the relationships between DDH expression and chemotherapy resistance in ovarian cancer patients.Using immunohistochemistry, expression of DDH was measured in 41 patients with epithelial ovarian cancers. All patients underwent primary debulking surgery, followed with six cycles of cisplatin-based chemotherapy. Normal ovarian tissues were obtained from patients with benign gynecologic diseases (n = 14). Expression of DDH was confirmed by reverse transcription-polymerase chain reaction. The correlation between DDH expression and clinico-pathological parameters was analyzed by statistical analysis. Difference of progression-free survivals between different groups was compared by a log-rank test.Eighteen ovarian cancer samples (43.9%) expressed DDH at a moderate to strong level. This marked a significant difference from the negligible expression (1/14, 7.1%) found in the control group (P = 0.02). Of interest, the clear cell adenocarcinoma revealed DDH overexpression (75%) and mucinous adenocarcinoma revealed low DDH expression (16.7%), although DDH expression did not show any significant variation according to different histotypes. DDH overexpression was found in a statistically significantly higher percentage of cisplatin-resistant cases (n = 8/11; 72.7%) than in cisplatin-sensitive cases (n = 9/27; 33.3%) (P = 0.037). Using multivariate analysis, only DDH retained as an independent role in predicting a poor chance of response to cisplatin-based treatment. DDH overexpression cases (median 12 months, 95% confidence interval 4-20) demonstrated a shorter progression-free survival than DDH-negative cases (median 28 months, 95% confidence interval 23-33), but this result did not reach the statistical significance (P = 0.1742). In the advance stage, the DDH-positive group has a shorter PFS as compared with DDH-negative group, and this result closely approaches the statistical significance (P = 0.0669).DDH is expressed in a high percentage of primary ovarian tumors and its expression may be associated with cisplatin-based chemotherapy resistance. The possible prognostic role of DDH in ovarian carcinoma deserves further study." @default.
• W2083001514 created "2016-06-24" @default.
• W2083001514 creator A5020069509 @default.
• W2083001514 creator A5030708845 @default.
• W2083001514 creator A5037523556 @default.
• W2083001514 creator A5048309885 @default.
• W2083001514 creator A5056632576 @default.
• W2083001514 creator A5057843840 @default.
• W2083001514 creator A5066406990 @default.
• W2083001514 date "2005-04-01" @default.
• W2083001514 modified "2023-10-15" @default.
• W2083001514 title "Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients" @default.
• W2083001514 cites W123822435 @default.
• W2083001514 cites W1589402586 @default.
• W2083001514 cites W1914677356 @default.
• W2083001514 cites W1965447478 @default.
• W2083001514 cites W1977085981 @default.
• W2083001514 cites W1988998235 @default.
• W2083001514 cites W1996213262 @default.
• W2083001514 cites W2028896946 @default.
• W2083001514 cites W2033352851 @default.
• W2083001514 cites W2043900159 @default.
• W2083001514 cites W2068776651 @default.
• W2083001514 cites W2069885515 @default.
• W2083001514 cites W2080767500 @default.
• W2083001514 cites W2086342143 @default.
• W2083001514 cites W2086433173 @default.
• W2083001514 cites W2087993487 @default.
• W2083001514 cites W2098645377 @default.
• W2083001514 cites W2109934093 @default.
• W2083001514 cites W2111729067 @default.
• W2083001514 cites W2113214957 @default.
• W2083001514 cites W2134107897 @default.
• W2083001514 cites W2142385577 @default.
• W2083001514 cites W3041047318 @default.
• W2083001514 doi "https://doi.org/10.1016/j.ygyno.2004.12.031" @default.
• W2083001514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15790446" @default.
• W2083001514 hasPublicationYear "2005" @default.
• W2083001514 type Work @default.
• W2083001514 sameAs 2083001514 @default.
• W2083001514 citedByCount "43" @default.
• W2083001514 countsByYear W20830015142012 @default.
• W2083001514 countsByYear W20830015142013 @default.
• W2083001514 countsByYear W20830015142014 @default.
• W2083001514 countsByYear W20830015142015 @default.
• W2083001514 countsByYear W20830015142016 @default.
• W2083001514 countsByYear W20830015142017 @default.
• W2083001514 countsByYear W20830015142020 @default.
• W2083001514 countsByYear W20830015142021 @default.
• W2083001514 countsByYear W20830015142022 @default.
• W2083001514 crossrefType "journal-article" @default.
• W2083001514 hasAuthorship W2083001514A5020069509 @default.
• W2083001514 hasAuthorship W2083001514A5030708845 @default.
• W2083001514 hasAuthorship W2083001514A5037523556 @default.
• W2083001514 hasAuthorship W2083001514A5048309885 @default.
• W2083001514 hasAuthorship W2083001514A5056632576 @default.
• W2083001514 hasAuthorship W2083001514A5057843840 @default.
• W2083001514 hasAuthorship W2083001514A5066406990 @default.
• W2083001514 hasConcept C121608353 @default.
• W2083001514 hasConcept C126322002 @default.
• W2083001514 hasConcept C142724271 @default.
• W2083001514 hasConcept C143998085 @default.
• W2083001514 hasConcept C146357865 @default.
• W2083001514 hasConcept C151730666 @default.
• W2083001514 hasConcept C204232928 @default.
• W2083001514 hasConcept C207886595 @default.
• W2083001514 hasConcept C2776694085 @default.
• W2083001514 hasConcept C2778239845 @default.
• W2083001514 hasConcept C2780427987 @default.
• W2083001514 hasConcept C2781100745 @default.
• W2083001514 hasConcept C2781182431 @default.
• W2083001514 hasConcept C71924100 @default.
• W2083001514 hasConcept C86803240 @default.
• W2083001514 hasConcept C90924648 @default.
• W2083001514 hasConceptScore W2083001514C121608353 @default.
• W2083001514 hasConceptScore W2083001514C126322002 @default.
• W2083001514 hasConceptScore W2083001514C142724271 @default.
• W2083001514 hasConceptScore W2083001514C143998085 @default.
• W2083001514 hasConceptScore W2083001514C146357865 @default.
• W2083001514 hasConceptScore W2083001514C151730666 @default.
• W2083001514 hasConceptScore W2083001514C204232928 @default.
• W2083001514 hasConceptScore W2083001514C207886595 @default.
• W2083001514 hasConceptScore W2083001514C2776694085 @default.
• W2083001514 hasConceptScore W2083001514C2778239845 @default.
• W2083001514 hasConceptScore W2083001514C2780427987 @default.
• W2083001514 hasConceptScore W2083001514C2781100745 @default.
• W2083001514 hasConceptScore W2083001514C2781182431 @default.
• W2083001514 hasConceptScore W2083001514C71924100 @default.
• W2083001514 hasConceptScore W2083001514C86803240 @default.
• W2083001514 hasConceptScore W2083001514C90924648 @default.
• W2083001514 hasIssue "1" @default.
• W2083001514 hasLocation W20830015141 @default.
• W2083001514 hasLocation W20830015142 @default.
• W2083001514 hasOpenAccess W2083001514 @default.
• W2083001514 hasPrimaryLocation W20830015141 @default.
• W2083001514 hasRelatedWork W162261237 @default.
• W2083001514 hasRelatedWork W1964714663 @default.
• W2083001514 hasRelatedWork W2053306150 @default.

• next